Anti-tumor Immunity and Mechanism of Immunosuppression Mediated by Tumor Cells: Role of Tumor-Derived Soluble Factors and Cytokines

REFERENCES

• Burnet FM. Cancer—A biological approach. BMJ 1957; 1: 841–847.
   PubMed Web of Science ®Google Scholar
• Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1–27.
   PubMed Web of Science ®Google Scholar
• Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7: 3–25.
   PubMedGoogle Scholar
• Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55: 329–333.
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, IFN-γ and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 2001; 410: 1107–1111.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991–998.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The Three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329–360.
   PubMed Web of Science ®Google Scholar
• Asghar SS. Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest 1995; 72: 254–271.
   PubMedGoogle Scholar
• Morgan BP, Rushmere NK, Harris CL. Therapeutic uses of recombinant complement receptors. Biochem Soc Trans 1998; 26: 49–54.
   PubMed Web of Science ®Google Scholar
• Matthews TJ, Collins JJ, Roloson GJ, Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. J Immunol 1981; 126: 2332–2336.
   PubMed Web of Science ®Google Scholar
• Ralph P, Nakoinz I. Differences in antibody dependent and nonspecific killing of tumor cells by macrophage cell lines. Cancer Res 1981; 41: 3546–3550.
   PubMedGoogle Scholar
• Hibbs J Jr, Taintor R, Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235:473–476.
   PubMedGoogle Scholar
• Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180: 211–222.
   PubMed Web of Science ®Google Scholar
• Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993; 7: 187–191.
   PubMedGoogle Scholar
• Nakano T, Oka K, Sugita T, Tsunemoto H. Anti-tumor activity of Langerhans cells in radiation therapy for cervical cancer and its modulation with SPG administration. In Vivo 1993; 7: 257–263.
   PubMedGoogle Scholar
• Ridge JP, Rosa F Di Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474–478.
   PubMed Web of Science ®Google Scholar
• Imahayashi S, Ichiyoshi Y, Yoshino I, Tumor-infiltrating B cell-derived IgG recognizes tumor. Cancer Invest 2000; 18: 530–536.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother Pharmacol 2000; 46: S3–S7.
   Google Scholar
• Cote RJ, Morrissey DM, Houghton AN, Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA 1983; 80: 2026–2030.
   PubMed Web of Science ®Google Scholar
• Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in anti-tumor immunity. Trends Immunol 2001; 22: 269–276.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–146.
   PubMedGoogle Scholar
• Fossati G, Taramelli D, Balsari A, Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer 1984; 33: 591–597.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Lackman RD, Ferrone S, Cellular immune response to human sarcomas. I. Development, phenotype and specificity. J Immunol 1986; 137: 3042–3048.
   PubMed Web of Science ®Google Scholar
• Berke G. Functions and mechanisms of lysis induced by cytotoxic T lymphocytes and natural killer cells. In: Paul WE (Ed.): Fundamental Immunology (2nd Ed.). New York: Raven Press, pp. 735–764, 1989.
   Google Scholar
• Rodolfo M, Salvi C, Bassi C, Parmiani G. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-1 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model. Cancer Immunol Immunother 1990; 31: 28–36.
   PubMedGoogle Scholar
• Young JD. Killing of target cells by lymphocytes: a mechanistic view. Physiol Rev 1989; 69: 250–314.
   PubMed Web of Science ®Google Scholar
• Herberman RB, Nunn ME, Holden HT, Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer 1977; 19: 555–564.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71: 907–920.
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanism of immune evasion by tumors. Adv Immunol 2006; 90: 51–81.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3–15.
   PubMed Web of Science ®Google Scholar
• Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 2002; 3: 999–1025.
   PubMed Web of Science ®Google Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cell with PD-1 on tumor specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 307–314.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267–296.
   PubMed Web of Science ®Google Scholar
• Manson LA. Does antibody-dependent epitope masking permit progressive tumor growth in the face of cell-mediated cytotoxicity. Immunol Today 1991; 12: 352–355.
   PubMedGoogle Scholar
• KE Hellström, Hellström I. Principles of tumor immunity, tumor antigens. In: VT DeVita Jr, Hellman S, Rosenberg SA (Eds.). Biological Therapy of Cancer. Philadelphia: Lippincott, p. 42, 1991.
   Google Scholar
• Baldwin RW, Robbins RA. Humoral factor abrogating cell-mediated immunity in the tumor-bearing host. Curr Topic Microbiol Immunol 1975; 72: 21–53.
   PubMedGoogle Scholar
• Hellström KE, Hellström I. Lymphocyte mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 1974; 18: 209–277.
   PubMedGoogle Scholar
• Haskill JS, Key M, Radov LA, The importance of antibody and macrophage in spontaneous and drug-induced regression of T1699 mammary adenocarcinoma. J Reticuloendo Soc 1979; 26: 417–425.
   PubMedGoogle Scholar
• Wood GW, Morantz RA, Tilzer SA, Gollahon KA. Immunoglobulin bound in vivo to Fc receptor positive cells in humans central nervous system tumor. J Natl Cancer Inst 1980; 64: 411–418.
   PubMedGoogle Scholar
• Wood GW, Tilzer SA, Gollahon KA, Lindsay JM. Association between immunoglobulin and IgG Fc receptors in primary methylcholanthrene induced sarcoma. Cancer Res 1979; 39: 4588–4593.
   PubMedGoogle Scholar
• Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumor infiltrating lymphocytes in breast cancer. Br J Cancer 1990; 62:971–975.
   PubMed Web of Science ®Google Scholar
• Szuro-Sudol A, Murray HW, Nathan CF. Suppression of macrophage antimicrobial activity by a tumor cell product. J Immunol 1983; 131: 384–387.
   PubMedGoogle Scholar
• Hasday JD, Shah EM, Lieberman AP. Macrophage TNF release is induced by contact with some tumors. J Immunol 1990; 145: 371–379.
   PubMed Web of Science ®Google Scholar
• Janicke R, Mannel DN. Distinct tumor cell membrane constitutes activate human monocyte for TNF synthesis. J Immunol 1990; 144: 1144–1150.
   PubMedGoogle Scholar
• Sotomayor EM, Fu YX, Lopez-Cepero M, Role of tumor-derived cytokines on the immune system of mice bearing adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol 1991; 147: 2816–2823.
   PubMedGoogle Scholar
• Hannigan BM, McNally OR, Kirrane O, Eason SJ. Tumor cell inhibition of macrophage cytokine activity. FEMS Microbiol Immunol 1992; 105: 283–288.
   Google Scholar
• Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokine and polysaccharide. Eur J Immunol 1994; 24: 435–439.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Sodhi A, Kumar R. Activation of murine macrophages by tumor cells. Int J Immunopathol Pharmacol 1995; 8: 45–56.
   Google Scholar
• Peters C, Lötzerich H, Niemeir B, Exercise, cancer and immune response of monocytes. Anticancer Res 1995; 15: 175–179.
   PubMed Web of Science ®Google Scholar
• Kumagai H, Masuda T, Sakashita M, Modulation of macrophage activity in tumor-bearing mice by cytogenin. J Antibiotics 1995; 48: 321–325.
   PubMed Web of Science ®Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Euro J Cancer 2004; 42: 717–727.
   Google Scholar
• Kumar S, Deepak P, Acharya A. Hsp70 modulates the enhanced production of reactive intermediate metabolites and a pro-inflammatory cytokine TNF-α expression in a T-cell lymphoma. Eur J Inflam 2006; 4: 157–169.
   Google Scholar
• Kumar S, Deepak P, Acharya A. Hsp70 induces Th1 polarization through tumor-associated macrophages in a T-cell lymphoma. Neoplasma 2007; 54: 113–122.
   PubMedGoogle Scholar
• North SM, Nicolson GL. Heterogeneity in the sensitivity of the 13762N rat mammary adenocarcinoma cell clones to cytolysia mediated by extra- and intra-tumoral macrophages. Cancer Res 1985; 45: 1453–1458.
   PubMed Web of Science ®Google Scholar
• McBridge WH. Phenotype and functions of intra-tumoral macrophages. Biochimica et Biophysica Acta 1986; 865: 27–41.
   PubMedGoogle Scholar
• Mantovani A, Bottazzi B, Colotta F, The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265–270.
   PubMedGoogle Scholar
• Andreesen R. Macrophage-directed tumor immunotherapy revisited past and future of an old doctor's dilemma. Immunol Res 1993; 144: 291–294.
   Google Scholar
• Evans R, Alexander P. Mechanism of immunologically specific killing of tumor cells by macrophages. Nature 1972; 236: 168–170.
   PubMed Web of Science ®Google Scholar
• Chapes SK, Gooding LR. Evidence for the involvement of cytotoxic macrophages in rejection of SV-40-induced tumors. J Immunol 1985; 135: 2192–2198.
   PubMedGoogle Scholar
• Yamazaki M, Okutomai T. Augmentation of release of cytotoxin from murine bone marrow and peritoneal macrophages by tumor transplantation. Cancer Res 1989; 49: 352–356.
   PubMedGoogle Scholar
• Garraud O, Faucher A, Legrand E. Impairment of monocyte functions in advanced head and neck cancer. Immunol Lett 1988; 18: 213–318.
   PubMed Web of Science ®Google Scholar
• Kan-Mitchell J, Hengst JC, Kempf RA, Cytotoxic activity of human pulmonary alveolar macrophages. Cancer Res 1985; 45: 453–458.
   PubMedGoogle Scholar
• Kerrebijn JD, Balm AJ, Knegt PP, Macrophages and dendritic cells infiltration in head and neck squamous cell carcinoma: An immunohistochemical study. Cancer Immunol Immunother 1994; 38: 31–37.
   PubMedGoogle Scholar
• Skew D, Burger CJ, Elgert KD. Tumor growth and adherence change the expression of macrophage Mac-2. Cancer Lett 1993; 69: 67–74.
   PubMedGoogle Scholar
• Walker TM, Burger CJ, Elgert KD. Tumor growth alters macrophage responsiveness to M-CSF during reactivity against allogeneic and syngeneic MHC class II molecules. Immunol Invest 1993; 22: 463–476.
   PubMed Web of Science ®Google Scholar
• Cameron DJ, Stromberg BV. The ability of head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors in cytotoxicity. Cancer 1984; 54: 2403–2408.
   PubMedGoogle Scholar
• Allen C, Hogg N. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 1987; 78: 465–470.
   PubMed Web of Science ®Google Scholar
• Kuda T, Yasumoto K, Yano T, Role of anti-tumor activity of alveolar macrophages in lung cancer patients. Cancer Res 1987; 47: 2199–2202.
   PubMedGoogle Scholar
• Jhaver K, De A, Advani S, Nadkarni J. Production of IL-1 and TNF in non-Hodgkin's lymphoma patients. Cancer Immunol Immunother 1991; 34:123–127.
   PubMedGoogle Scholar
• Evans R, Haskill S. In: Herberman RB, Friedman H (Eds.). The Reticuloendothelial System. A Comprehensive Treatise (Cancer Vol. 5). New York: Plenum Press, pp. 155–176, 1983.
   Google Scholar
• Almand B, Resser J, Lindman B, Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755–1766.
   PubMed Web of Science ®Google Scholar
• Almand B, Clark J, Nikitina E, Increased production of immature myeloid cells in cancer patients as a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678–689.
   PubMed Web of Science ®Google Scholar
• Bronte V, Apolloni E, Cabrelle A, Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838–3846.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 6: 293–198.
   Google Scholar
• Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000; 164: 2214–2220.
   PubMed Web of Science ®Google Scholar
• Bloom ET, Babbit JT. Monocyte-mediated augmentation of human natural cell-mediated cytotoxicity. Cell Immunol 1985; 91: 21–32.
   PubMedGoogle Scholar
• DeBoer KP, Braun DP, Harris JE. Natural cytotoxicity and antibody-dependent cytotoxicity in solid tumor cancer patients: Regulation by the adherent cells. Clin Immunol Immunopathol 1982; 23: 133–144.
   PubMedGoogle Scholar
• Schulof RS, Michitsch RW, Livingston PO, Gupta S. Monocyte-mediated suppression of lymphocyte cytotoxic activity for cultured autologous melanoma cells. Cell Immunol 1981; 57: 529–532.
   PubMed Web of Science ®Google Scholar
• Roth MD, Golub SH. Inhibition of LAK cell function by alveolar macrophages. Cancer Res 1989; 49: 4690–4695.
   PubMed Web of Science ®Google Scholar
• Grouard G, Rissoan MC, Filgueira L, The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD-40-ligand. J Exp Med 1997; 185: 1101–1111.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007; 121: 149–157.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Plasmacytoid dendritic cells induce plasma cell differentiation through type-1 interferon and interleukin-6. Immunity 2003; 19: 225–234.
   PubMed Web of Science ®Google Scholar
• Poeck H, Wagner M, Battiany J, Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T cell help. Blood 2004; 103: 3058–3064.
   PubMed Web of Science ®Google Scholar
• Tabera S, Perez-Simon JA, Diez-Campelo M, The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B lymphocytes. Haematologica 2008; 93: 1301–1309.
   PubMed Web of Science ®Google Scholar
• Rissoan M, Soumelis V, Kadowaki N, Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183–1186.
   PubMed Web of Science ®Google Scholar
• Salio M, Cella M, Vermi W, Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33: 1052–1062.
   PubMed Web of Science ®Google Scholar
• Hartmann E, Wollenberg B, Rothenfusser S, Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478–6487.
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Zou L, Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65: 5020–5026.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target. Cancer Cell 2009; 16: 309–323.
   PubMed Web of Science ®Google Scholar
• Fu Y, Paul RD, Wang Y, Lopez DM. Thymic involution and thymocyte phenotypic alteration induced by murine mammary adenocarcinomas. J Immunol 1989; 143: 4300–4307.
   PubMed Web of Science ®Google Scholar
• Lopez DM, Paul RD. Analysis of lymphoid cells responding to virus and tumor-associated antigens in spleens of syngenic mouse mammary tumor systems with low and high oncogenic potentials. J Natl Cancer Inst 1982; 69: 1403–1409.
   PubMedGoogle Scholar
• Zou JP, Shimizu J, Ikegame K, Tumor-immunotherapy with the use of tumor antigen-pulsed antigen presenting cells. Cancer Immunol Immunother 1992; 35: 1–6.
   PubMedGoogle Scholar
• Gregorian SK, Battisto JR. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources. Cancer Immunol Immunother 1990; 31: 325–334.
   PubMed Web of Science ®Google Scholar
• Tada T, Sano H, Sato S, Immune dysfunction expressed selectively on L3T4+ T cells in the tumor-bearing state. J Leukoc Biol 1990;47: 149–157.
   Google Scholar
• Tada T, Ohzeki S, Utsumi K, Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077–1082.
   PubMed Web of Science ®Google Scholar
• Li XF, Takiuchi H, Zou JP, Transforming growth factor-β-mediated immunosuppression in tumor-bearing state: Enhanced production of TGF-β and a progressive increase in TGF-β susceptibility of anti-CD4+ cell function. Jpn J Cancer Res 1993; 84: 315–325.
   PubMedGoogle Scholar
• Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995; 155: 3124–3134.
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, O’Shea JJ, Longo DL, Alteration in signal transduction molecule in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795–1798.
   PubMed Web of Science ®Google Scholar
• Travis J. Do tumor-altered T cells depress immune responses? Science 1992; 258: 1732–1733.
   PubMed Web of Science ®Google Scholar
• Goedegebuure PS, Eberlin TJ. The role of CD4+ tumor infiltrating lymphocytes in human solid tumors. Immunol Res 1995; 14: 119–131.
   PubMedGoogle Scholar
• Kurt RA, Park JA, Panelli MC, T lymphocytes infiltrating sites of tumor rejection and progression, display identical V usage for different cytotoxic activities. J Immunol 1995;154: 3969–3974.
   PubMedGoogle Scholar
• Mukherjee BN, Chakraborty G, Sivanandan M. T cell clones that reacts against autologous human tumor. Immunol Rev 1990; 116: 33–62.
   PubMedGoogle Scholar
• Yoshino I, Yano T, Murata T, Tumor reactive T cells accumulate in lung cancer tissue but fail to respond due to tumor-derived factors. Cancer Res 1992; 52: 775–781.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Jost LM, Herberman RB. Tumor infiltrating lymphocytes: Potential and limitations of their use for cancer therapy. Crit Rev Oncol Hematol 1992; 12: 25–47.
   PubMedGoogle Scholar
• Marx J. The T cell receptor begins to reveal its many facets. Science 1995; 267: 459–460.
   PubMedGoogle Scholar
• Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295–307.
   PubMed Web of Science ®Google Scholar
• Mittal S, Marshall NA, Duncan L, Local and systemic induction of CD4+CD25+ regulatory T cell population by non-Hodgkin's lymphoma. Blood 2008; 111: 5359–5370.
   PubMed Web of Science ®Google Scholar
• Baumgartner J, Wilson C, Palmer B, Melanoma induces immunosuppression by up-regulating FoxP3(+) regulatory T cells. J Surg Res 2007; 141: 72–77.
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20: 241–246.
   PubMed Web of Science ®Google Scholar
• Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor specific tolerance. J Immunol 2007; 178: 2155–2162.
   PubMed Web of Science ®Google Scholar
• Grossman W, Verbsky J, Barchet W, Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589–601.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Chiesa MD, Transforming growth factor β 1 inhibits expression of NK p30 and NKG2D receptor. Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003; 100:4120–4125.
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172: 5149–5153.
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–1886.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, Coombes J, Mottet C, Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006; 177: 5852–5860.
   PubMedGoogle Scholar
• Kamanaka M, Kim ST, Wan YY, Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knock in tiger mouse. Immunity 2006; 25: 941–952.
   PubMed Web of Science ®Google Scholar
• Tato CM, JJ O’Shea. Immunology: What does it mean to be just 17? Nature 2006; 441: 166–168.
   PubMed Web of Science ®Google Scholar
• Fossiez F, Banchereau J, Murray R, Interleukin-17. Int Rev Immunol 1998; 16: 541–551.
   PubMedGoogle Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179–189.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB, Transforming growth factor-β induces development of the T(H)17 lineage. Nature 2006; 441: 231–234.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235–238.
   PubMed Web of Science ®Google Scholar
• Miyahara Y, Odunsi K, Chen W, Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Nat Ass Sci USA 2008; 105: 15505–15510.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123–1132.
   PubMed Web of Science ®Google Scholar
• Zhu J, Davidson TS, Wei G, Down-regulation of Gfi-1 expression by TGF-β is important for differentiation of Th17 and CD103+ inducible regulatory T cells. J Exp Med 2009; 206: 329–341.
   PubMedGoogle Scholar
• Stutman O, Figarella EF, Paige CJ. Natural cytotoxic (NC) cells against solid tumors in mice: General characteristics and comparison to natural killer (NK) cells. In: Herberman RB (Ed.): Natural Cell-Mediated Immunity against Tumors. New York: Academic Press, p. 187, 1980.
   Google Scholar
• Ehrlich R, Efrate M, With IP. Cytotoxicity and cytostasis mediated by splenocytes of mice subjected to chemical carcinogens and of mice bearing primary tumors. In: Herberman RB (Ed.): Natural Cell-Mediated Immunity against Tumors. New York: Academic Press, p. 1073, 1980.
   Google Scholar
• Gerson JM. Systemic and in situ natural killer activity in tumor-bearing mice and patients with cancer. In: Herberman RB (Ed.): Natural Cell-Mediated Immunity against Tumors. New York: Academic Press, p. 1047, 1980.
   Google Scholar
• Lala PK, Santer V, Libenson H, Parhar RS. Changes in host NK cell population in mice during tumor development. I. Kinetics and in vivo significance. Cell Immunol 1985; 93: 250–264.
   PubMed Web of Science ®Google Scholar
• Moy PM, Holmes EC, Golub SH. Depression of NK cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 1985; 45:57–60.
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Matsuzaki G, Harada M, Early appearance and activation of NK cells in human tumor-infiltrating lymphoid cells during tumor development. Eur J Immunol 1993; 23: 1029–1033.
   PubMedGoogle Scholar
• Budzynski W, Chirigas M, Gruys E. Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2. Cancer Immunol Immunother 1987; 24: 253–258.
   PubMedGoogle Scholar
• Parhar RS, Lala PK. Changes in host NK cell population in mice during tumor development. II. Mechansim of suppression of NK activity. Cell Immunol 1985; 93: 265–279.
   PubMed Web of Science ®Google Scholar
• Maeurer MJ, Martin DM, Castelli C, Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995; 41: 111–121.
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295–307.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989–999.
   Google Scholar
• Murgita RA, Tormasi TB. Suppression of the immune response by alpha-feto-protein. J Exp Med 1975; 141: 269–286.
   PubMed Web of Science ®Google Scholar
• Oh SK, Moolton FL. Nonspecific immunosuppressive factors in malignant ascites: Further characterization and possible relationship to erythrocyte receptors of human peripheral T cells. J Immunol 1981; 127: 2300–2307.
   PubMed Web of Science ®Google Scholar
• Nelson M, Nelson DS. Macrophages and resistance to tumors. I. Inhibition of delayed-type hypersensitivity reactions by tumor cells and by soluble products affecting macrophages. Immunology 1978; 34: 277–290.
   PubMedGoogle Scholar
• Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000; 164: 2214–2220.
   PubMed Web of Science ®Google Scholar
• Fulton AM, Heppner GH. Relationship of prostaglansin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinoma. Cancer Res 1985; 45: 4779–4784.
   PubMed Web of Science ®Google Scholar
• Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: role of tumor-derived IL-10, TGF-β, and prostaglandin E2. J Immunol 1994; 153: 1674–1686.
   PubMed Web of Science ®Google Scholar
• Myers MJ, Hanafin WP, Schook LB. Augmented PGE2 production following exposure to dimethylnitrosamine in vitro: Relevance to suppressed T cell responses. Immunophrmacol 1989; 18;115–124.
   Google Scholar
• Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006; 25: 323–331.
   PubMed Web of Science ®Google Scholar
• Harizi H, Juzan M, Pitard V, Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002; 68: 2255–2263.
   Google Scholar
• Sombroek CC, Stam AGM, Masterson AJ, Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002; 168: 4333.
   PubMed Web of Science ®Google Scholar
• Gemsa D, Leser HG, Deimann W, Resch K. Suppression of T cell proliferation during lymphoma growth in mice: Role of PGE2-producing suppressor macrophages. Immunobiology 1982; 161: 385–391.
   PubMed Web of Science ®Google Scholar
• Gregorian SK, Battisto JR. Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotype and examination of elimination of suppression. Cancer Immunol Immunother 1990; 31:335–341.
   PubMedGoogle Scholar
• Hakamori S. Structure, organization, and function of glycosphigolipids in membrane. Curr Opin Hematol 2003; 10: 16–24.
   PubMedGoogle Scholar
• Hakamori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 1981; 50: 733–764.
   PubMedGoogle Scholar
• Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 1983; 43:3808–3813.
   PubMed Web of Science ®Google Scholar
• Bharti AC, Singh SM. Induction of apoptosis in bone marrow cells by gangliosides produced by a T cell lymphoma. Immunol Lett 2000; 72: 39–48.
   PubMed Web of Science ®Google Scholar
• Bharti AC, Singh SM. Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. Int Immunopharmacol 2001; 1: 155–165.
   PubMed Web of Science ®Google Scholar
• Birklé S, Zeng G, Gao L, Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85: 455–463.
   PubMedGoogle Scholar
• Shurin GV, Shurin MR, Bykovskaia S, Neuroblastoma-derived gangliosides inhibit dendritic cell generation function. Cancer Res 2001; 61: 363–369.
   PubMed Web of Science ®Google Scholar
• Péguet-Navarro J, Sportouch M, Popa I, Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003; 170: 3488–3494.
   PubMedGoogle Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.
   PubMed Web of Science ®Google Scholar
• Ohm JE, Shurin MR, Esche C, Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999; 163: 3260–368.
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150–4166.
   PubMed Web of Science ®Google Scholar
• Bronte V, Chappell DB, Apolloni E, Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162: 5728–5737.
   PubMed Web of Science ®Google Scholar
• Fu Y, Watson G, Jimenez JJ, Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990; 50: 227–234.
   PubMed Web of Science ®Google Scholar
• Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999; 21:241–252.
   PubMed Web of Science ®Google Scholar
• Serafini P, Carbley R, Noonan KA, High dose GM-CSF-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337–6343.
   PubMed Web of Science ®Google Scholar
• Young M, Wright M, Young M. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Cancer Immunol Immunother 1991; 33: 146–152.
   PubMed Web of Science ®Google Scholar
• Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22:3188–3192.
   PubMed Web of Science ®Google Scholar
• Fixe P, Praloran V. Macrophage colony-stimulating-factor (M-CSF or CSF-1) and its receptor: Structure-function relationships. Eur Cytokine Netw 1997; 8: 125–136.
   PubMed Web of Science ®Google Scholar
• Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: Complexity in action. Trends Cell Biol 2004; 14: 628–638.
   PubMed Web of Science ®Google Scholar
• Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006; 18: 39–48.
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Montmain G, Dieu MC, Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony stimulating factor. Blood 1998; 92: 4778–4791.
   PubMedGoogle Scholar
• Ding A, Nathan CF, Graycar J, Macrophage deactivating factor and transforming growth factor 1, 2, and 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ. J Immunol 1990; 145: 940–944.
   PubMed Web of Science ®Google Scholar
• Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60: 247–267.
   PubMed Web of Science ®Google Scholar
• Lindeskog M, Medstrand P, Blomberg J. Sequence variation of human endogenous retrovirus ERV-9 related elements in an env region corresponding to an immunosuppressive peptide: Transcription in neoplastic cells. J Virol 1993; 67: 1122–1126.
   PubMedGoogle Scholar
• Lindvall M, Sjogren HO. Inhibition of rat yolk sac tumor growth in vivo by a monoclonal antibody to the retroviral molecule P15E. Cancer Immunol Immunother 1991; 33: 21–27.
   PubMedGoogle Scholar
• Amar M, Amit N, Babin-Chevaye C, Effect of a factor released by K562 malignant cells in culture on human neutrophil bactericidal activity. Infect Immun 1991; 59: 2673–2676.
   PubMedGoogle Scholar
• Janicke R, Mannel DN. Distinct tumor cell membrane constituents activate human monocyte for TNF synthesis. J Immunol 1990; 144: 1144–1150.
   PubMedGoogle Scholar
• Hoffman RA, Langrehr JM, Billiar TR, Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990; 145: 2220–2226.
   PubMed Web of Science ®Google Scholar
• Mills CD. Molecular basis of “suppressor” macrophages. Arginine metabolism via NO synthase pathway. J Immunol 1991; 146: 2719–2723.
   PubMed Web of Science ®Google Scholar
• Webb DS, Shimizu Y, van Seventer GA, LFA-3, CD44 and CD45: Physiologic trigger of human monocyte TNF and IL-1 release. Science 1990; 249: 1295–1297.
   PubMed Web of Science ®Google Scholar
• Metzger Z, Hoffeld JT, Oppenheim JJ. Macrophage mediated suppression: Evidence for participation of both hydrogen peroxide and prostaglandin in suppression of murine lymphocytes proliferation. J Immunol 1980; 124: 983–988.
   PubMed Web of Science ®Google Scholar
• Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005; 10: 1881–1896.
   PubMedGoogle Scholar
• Hofmann T, Schmitt B, Mack B, New target genes for tumor-derived soluble factors in primary monocytes. Cancer Genom Proteom 2004; 1: 167–176.
   PubMedGoogle Scholar
• Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. J Immunol Rev 2004; 22: 275–293.
   Google Scholar
• Ben-Baruch A. Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006; 16: 38–52.
   PubMedGoogle Scholar
• Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 2005; 6: 1182–1190.
   PubMed Web of Science ®Google Scholar
• Luo J-L, Maeda S, Hsu L-C, Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297–305.
   PubMedGoogle Scholar
• Yang H, Bocchetta M, Kroczynska B, TNF-α inhibits asbestos-induced cytotoxicity by a NF-kB-dependent pathway, a possible mechanism for asbestos-induced tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 345–505.
   Google Scholar
• Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276–285.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16: 35–53.
   PubMed Web of Science ®Google Scholar
• Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol 1998; 64: 275–290.
   PubMed Web of Science ®Google Scholar
• Moore RJ, Owens DM, Stamp G, Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828–831.
   PubMed Web of Science ®Google Scholar
• Arnott CH, Scott KA, Moore RJ, Expression of both TNF-α receptor subtypes is essential for optimal skin tumor development. Oncogenes 2004; 23:1902–1910.
   PubMed Web of Science ®Google Scholar
• LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66–75.
   PubMed Web of Science ®Google Scholar
• Takeda K, Smyth MJ, Cretney E, Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 161–169.
   PubMed Web of Science ®Google Scholar
• Watford WT, Hissong BD, Bream JH, Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004; 202: 139–156.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–146.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB, Transforming growth factor-β induces development of the TH17 lineage. Nature 2006; 441: 231–234.
   PubMed Web of Science ®Google Scholar
• Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleuikin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155–174.
   PubMed Web of Science ®Google Scholar
• Witowski J, Ksiazek K, Jorres A. Interleukin-17: A mediator of inflammatory responses. Cell Mol Life Sci 2004; 61: 567–579.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233–240.
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin-17. Nat Immunol 2005; 6:1133–1141.
   PubMed Web of Science ®Google Scholar
• Ruddy MJ, Wong GC, Liu XK, Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004; 279: 2559–2567.
   PubMed Web of Science ®Google Scholar
• Tartour E, Fossiez F, Joyeux I, Interleukin-17, a T cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999; 59: 3698–3704.
   PubMed Web of Science ®Google Scholar
• Numasaki M, Watanabe M, Suzuki T, IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2 dependent angiogenesis. J Immunol 2005; 175:6177–6189.
   PubMed Web of Science ®Google Scholar
• Numasaki M, Fukushi J-I, Narula SK, Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620–2627.
   PubMed Web of Science ®Google Scholar
• Hao JS, Shan BE. Immune enhancement and anti-tumor activity IL-23. Cancer Immunol Immunother 2006; 55: 1426–1431.
   PubMed Web of Science ®Google Scholar
• Cho ML, Kang JW, Moon YM, STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006; 176: 5652–5661.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, IL-23 promotes tumor incidence and growth. Nature 2006; 442: 461–465.
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan AD, Zamorano J, The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701–738.
   PubMed Web of Science ®Google Scholar
• Santra S, Ghosh SK. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma. Cancer Immunol Immunother 1997; 44: 291–300.
   PubMedGoogle Scholar
• Conticello C, Pedini F, Zeuner A, IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic poteins. J Immunol 2004; 172: 5467–5477.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang J, Wang Z, Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 2008; 68: 8668–8687.
   Google Scholar
• Takeuchi T, Ueki T, Sasaki Y, Th2-like response and anti-tumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 1997; 43: 375–781.
   PubMed Web of Science ®Google Scholar
• Fallon PG, Jolin HE, Smith P, IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002; 17: 7–17.
   PubMed Web of Science ®Google Scholar
• Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357–368.
   PubMed Web of Science ®Google Scholar
• Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502–2512.
   PubMed Web of Science ®Google Scholar
• Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315–324.
   PubMedGoogle Scholar
• Osborne J, Moore PS, Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signalling and survival pathways. Hum Immunol 1999; 60:921–927.
   PubMed Web of Science ®Google Scholar
• Bommert K, Bargou RC, Stuhmer T. Signaling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574–1580.
   PubMed Web of Science ®Google Scholar
• Becker C, Fantini MC, Schramm C, TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491–501.
   PubMed Web of Science ®Google Scholar
• Cozen W, Gill PS, Ingles SA, IL-6 levels and genotypes are associated with risk of young adult Hodgkin lymphoma. Blood 2004; 103: 3216–3221.
   PubMed Web of Science ®Google Scholar
• Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumor sites induces subsequent generation of CD4+ T-regulatory cells and systemic collapse of anti-tumor immunity. Immunology 2001; 103: 449–457.
   PubMed Web of Science ®Google Scholar
• Moore KW, Waal Malefyt R de, Coffman RL, A O’Garra. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001; 19: 683–765.
   PubMed Web of Science ®Google Scholar
• Yang AS, Lattime EC. Tumor-induced IL-10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63: 2150–2157.
   PubMed Web of Science ®Google Scholar
• Steinbrink K, M Wölfl, Jonuleit H, Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772–4780.
   PubMed Web of Science ®Google Scholar
• Allavena P, Piemonti L, Longoni D, IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359–369.
   PubMed Web of Science ®Google Scholar
• Mullins DW, Martins RS, Burger CJ, Elgert KD. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. J Leukoc Biol 2001; 69: 129–137.
   PubMedGoogle Scholar
• McKenzie AN, Li X, Largaespada DA, Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993; 150: 5436–5444.
   PubMed Web of Science ®Google Scholar
• McKenzie AN, Culpepper JA, Waal Malefyt R de, IL-13, a T cell derived cytokine that regulates human monocyte and B cell function. Proc Natl Acad Sci USA 1993; 90: 3735–3739.
   PubMed Web of Science ®Google Scholar
• Minty A, Chalon P, Derocq JM, Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362: 248–250.
   Google Scholar
• Waal Malefyt R de, Figdor CG, Huijbens R, Effects of IL-13 on phenotype, cytokine production and cytotoxic function of human monocytes: Comparison with IL-4 and modulation by IFN-γ or IL-10. J Immunol 1993; 151: 6370–6381.
   PubMedGoogle Scholar
• VerceUi D, Jabara HH, Lee DW, Human recombinant interleukin 4 induces FcεR2/CD23 on normal human monocytes. J Exp Med 1988; 167:1406–1416.
   PubMedGoogle Scholar
• Te Velde AA, Klomp JPG, Yard BA, Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol 1988; 140: 1548–1554.
   PubMedGoogle Scholar
• Littman BH, Dastvan FF, Carlson PL, Sanders KM. Regulation of monocyte/macrophage C2 production and HLA-DR expression by IL-4 (BSF-1) and IFN-γ. J Immunol 1989; 142: 520–525.
   PubMed Web of Science ®Google Scholar
• Te Velde AA, Rousset E, Peronne C, IFN-γ and IFN-γ have different regulatory effects on IL-4 induced membrane expression of FcεRIIb and release of soluble FcεRIIb by human monocytes. J Immunol 1990; 144: 3052–3059.
   PubMedGoogle Scholar
• Becket S, Daniel EG. Antagonistic and additive effects of IL-4 and IFN-γ on human monocytes and macrophages: Effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 1990; 129: 351–362.
   PubMedGoogle Scholar
• Gerrard TL, Dyer DR, Mostowski HS. IL-4 and granulocyte-macrophage colony stimulating factor selectively increase HLA-DR and HLA-DP antigens, but not HLADQ antigens on human monocytes. J Immunol 1990; 144: 4670–4674.
   PubMed Web of Science ®Google Scholar
• Bogdan C, Nathan C. Modulation of macrophage functions by transforming growth factor β, interleukin-4, and interleukin-10. Ann NY Acad Sci 1993; 685: 713–739.
   PubMed Web of Science ®Google Scholar
• Hart PH, Vitti GF, Burgess DR, Potential anti-inflammatory effects of interleukin 4: Suppression of human monocyte tumor necrosis factor ct, interleukin 1 and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3803–3087.
   PubMed Web of Science ®Google Scholar
• Essner R, Rhoades K, McBride WH, IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857–3861.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Fenton MJ, Kaufman JD, Gerrard TL. IL-1 expression in human monocytes is transcriptionally and post-transcriptionally regulated by IL-4. J Immunol 1991; 146: 3431–3436.
   PubMed Web of Science ®Google Scholar
• Hamilton JA, Whitty GA, Royston AKM, Interleukin 4 suppresses granulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor levels in stimulated human monocytes. Immunology 1992; 76: 566–571.
   PubMed Web of Science ®Google Scholar
• Punnonen J, Aversa G, Cocks BG, Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730–3734.
   PubMed Web of Science ®Google Scholar
• BG Cocks, Waal Malefyt R de, Galizzi J-P, IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 1993; 5: 657–663.
   PubMedGoogle Scholar
• Defrance T, Carayon P, Billian G, Interleukin 13 is a B cell stimulating factor. J Exp Med 1994; 179: 135–143.
   PubMed Web of Science ®Google Scholar
• Punnonen J, Vries JE de. IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. J Immunol 1994; 152:1094–1102.
   PubMedGoogle Scholar
• Tangye SG, Ferguson A, Avery DT, Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol 2002; 169:4298–4306.
   Google Scholar
• Lai YH, Mosmann TR. Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production. J Immunol 1999; 162: 78–87.
   PubMed Web of Science ®Google Scholar
• Bost KL, Holton RH, Cain TK, Clements JD. In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice. Immunology 1996; 87: 633–641.
   PubMedGoogle Scholar
• Ford D, Sheehan C, Girasole C, The human B cell response to IL-13 is dependent on cellular phenotype as well as mode of activation. J Immunol 1999; 163: 3185–3193.
   PubMedGoogle Scholar
• Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 2005; 68: 302–310.
   PubMed Web of Science ®Google Scholar
• Zurawski G, Vries JE de. Interleukin-13, an interleukin-4 like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15: 19–26.
   PubMedGoogle Scholar
• Vries JE de. The role of IL-I 3 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102: 165–169.
   PubMedGoogle Scholar
• Gauchat JF, Schlagenhauf E, Feng NP, A nobel 4-kd interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells including an alternate type II interleukin-4/Interleukin-13 receptor. Eur J Immunol 1997; 27: 971–978.
   Google Scholar
• Curiel RE, Lahesmaa R, Subleski J, Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene. Eur J lmmunol 1997; 27: 1982–1987.
   PubMed Web of Science ®Google Scholar
• Jinquan T, Deleuran B, Gesser H, Regulation of human T lymphocyte chemotaxis in vitro by T cell-derived cytokines IL-2, IFN-y, IL-4, IL-10 and IL-13. J Immunol 1995; 154: 3742–3752.
   PubMedGoogle Scholar
• Terabe M, Matsui S, Noben-Trauth N, NKT cell-mediated repression of tumor-immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515–520.
   PubMed Web of Science ®Google Scholar
• Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of antitumor immunity and tumor growth. Cancer Immunol Immunother 2004; 53: 79–85.
   PubMed Web of Science ®Google Scholar
• Chen WJ, Wahl SM. TGF-β: The missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003; 14: 85–89.
   PubMed Web of Science ®Google Scholar
• Becker C, Fantini MC, Neurath MF. TGF-β as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 2006; 17: 97–106.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Puig PE, Roux S, Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 919–929.
   PubMed Web of Science ®Google Scholar
• Yang X, Letterio JJ, Lechleider RJ, Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 1999; 18: 1280–1291.
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117–129.
   PubMed Web of Science ®Google Scholar
• Chen M-L, Pittet MJ, Gorelik L, Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419–424.
   PubMedGoogle Scholar
• Ghiringhelli F, Ménard C, Terme M, CD4+CD25 +regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 2005; 202: 1075–1085.
   PubMed Web of Science ®Google Scholar